08:20 AM EST, 01/15/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) rose 6.5% in U.S. pre-market trading on Wednesday after saying that following a safety review, Germany's medical regulator approved continuing patient enrollment into Cohort 5 of the GOBLET study.

This cohort is evaluating pelareorep in combination with modified Folfirinox with or without the immunotherapy drug atezolizumab in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.

Early safety data will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year, Oncolytics said.

GOBLET is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany.

Oncolytics was last seen up US$0.05, to US$0.86, in New York trading.